Skip to content
Screener

Ironwood Pharmaceuticals IRWD Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$47.7MMiss by $3.2M
EPS-$0.01Miss by $0.03
Revenue estimate$50.9M
EPS estimate$0.02

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$120.0M
EPS estimate$0.30

Financials

Q4 2025

Income statement

See full
Revenue$47.7M-47.3%
Operating income$6.8M-78.4%
Net income-$2.3M-201%
EPS (diluted)-$0.01-200%

Balance sheet

See full
Cash & equivalents$215.5M+143%
Total debt$212.8M+1,274%
Total equity-$261.8M+13.1%
Total assets$396.9M+13.1%

Cash flow

See full
Operating cash flow$74.6M+390%
CapEx-—
Free cash flow$74.6M+390%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$548.23M-22.7%
Enterprise value$545.57M-14.2%
P/E22.8×-783×
P/S1.9×-0.2×

Profitability

See full
Operating margin33.3%+6.8pp
Net margin8.1%+7.9pp

Returns & leverage

See full
Current ratio1.1×-3.6×

FAQ

When did Ironwood Pharmaceuticals report Q4 2025 earnings?
Ironwood Pharmaceuticals (IRWD) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Ironwood Pharmaceuticals's Q4 2025 revenue and EPS?
Ironwood Pharmaceuticals reported revenue of $47.7M and eps of $-0.01 for Q4 2025.
Did Ironwood Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $50.9M by $3.2M. EPS missed the consensus estimate of $0.02 by $0.03.
How did Ironwood Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 47.3% from $90.5M a year earlier.
Where can I find Ironwood Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-019405) and the 10-K periodic report (0001104659-26-020489) directly on SEC EDGAR. The filing index links above go to sec.gov.